Articles by Emily Menendez
The benefits of PSA screening alone are offset by excess negative biopsies and the over-detection of low-grade cancers.
The IGCCCG was used to compare the survival probabilities of patients with testicular GCTs with or without teratoma.
The ARON-1 study investigated the efficacy of 1L treatment with TKIs versus IO-based combinations in patients with pRCC.
A case study studied the results of 4 patients with locally advanced or oligometastatic UC with complete response on imaging.
The results of this study are similar to previous data from the phase 3 CONTACT-03 trial.
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
While most STMs are benign, between 13% and 21% are malignant, and distinguishing between them remains a challenge.
cN1 patients with PCa who undergo initial treatment with RT have worse PCSM outcomes than those treated with RP.
The nomogram is used preoperatively to determine the probability of nodal tropism.
Survivors with high CIPN experienced more side effects compared to those with low CIPN.
For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative.
A combination of androgen annihilation therapy with radiotherapy was tested for recurrent metastatic prostate cancer.
Data from the JAVELIN Renal 101, KEYNOTE-426, CheckMate 9ER, CLEAR, and IMmotion151 trials were reviewed.
Relugolix was approved in 2020 for the treatment of localized prostate cancer based on the efficacy seen in the HERO trial.
The NRG-GU003 trial examined patients with prostate cancer who underwent hypofractionated and conventional radiotherapy.
While ICIs have become a novel treatment option for mUC, attrition rates may affect their impact on long-term survival.
RMC has a 3-year survival rate of less than 5% and responds poorly to other treatments for renal malignancies.
FASTRACK II was the first trial of its kind to examine nonsurgical definitive therapy in patients with primary RCC.
Gastrin-releasing peptide receptors may be overexpressed in prostate cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.